Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption

Purpose: Aromatase inhibitors are potent suppressors of breast cancer growth, but side effects include bone loss, fractures, arthralgias, and myalgias. We hypothesize vitamin D administration might be beneficial in treating these symptoms and to protect bone.
Study Start Date: April 2009
Estimated Study Completion Date: April 2013
Sponsor: Stanford University
Collaborator: Department of Defense ClinicalTrials.gov Identifier: NCT00904423

Ixabepilone to Treat Cervical Cancer

Objective: To determine whether ixabepilone is effective for treating cervical cancer.
Background: Ixabepilone is a member of the class of drugs called epithilones. These drugs interfere with the ability of cancer cells to replicate. Epithilones are similar to taxanes, another class of drugs, which includes the drug Taxol®. Taxol is widely used to treat a variety of cancers. Ixabepilone can work in cells that are resistant to Taxol.
Study Start Date: November 2008
Estimated Study Completion Date: April 2011
Sponsor: NCI
ClinicalTrials.gov Identifier: NCT00924066

Human Papillomavirus (HPV) and Risk of Cervical Precancer and Cancer

Objective: To determine whether certain types of HPV are more risky than others and, if so, whether they warrant separate detection in screening for cervical precancer and cancer. To determine if lasting infection by different HPV types can carry different risk of cervical precancer and cancer. To determine what viral and genetic factors influence the development of cervical precancer and cancer. To evaluate new HPV tests and new biomarkers of cervical cancer risk.

Background: In most women, HPV infection does not cause symptoms and the infection goes away on its own. In a small percentage of women, the HPV infection does not go away and sometimes can result in cervical precancer or cancer. There are several different types of HPV. A better understanding of which types are related to cervical precancer and cancer may help guide doctors in better clinical management of women who test positive for HPV and help them better understand why some women develop disease while others do not.
Sponsor: NCI
ClinicalTrials.gov Identifier: NCT00435214

Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Rationale: Developing a symptom management plan may help relieve symptoms related to cancer or cancer treatment and help improve quality of life.
Purpose: This randomized clinical trial is studying two different symptom management programs to see how well they work compared with usual care in patients with recurrent or persistent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Study Start Date: January 2010
Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Sponsor: Gynecologic Oncology Group
Collaborator: NCI
ClinicalTrials.gov Identifier: NCT00958698

back to August articles